


RANDOX



VIVALYTIC

THE ALL IN ONE
MOLECULAR SOLUTION



MAKING A POINT TO CARE

55 Diamond Road,
Crumlin,
Co. Antrim,
United Kingdom,
BT29 4QY

Email. marketing@randox.com

Tel. +44 (0) 28 9442 2413

CONTENTS

1

Vivalytic & Cartridges

Vivalytic	03
Vivalytic Cartridges	05
Vivalytic Workflow	07

2

Vivalytic Test Menu

Respiratory Infection Testing	11
Hospital Acquired Infection Testing	14
Genitourinary Infection Testing	17

3

Vivalytic Specification

Specifications	23
Vivasuite	24

4

Vivalytic Ordering Information

Ordering Information	27
----------------------	----



Please fill cartridge and insert into slot.

x

ID 34234623

eppendorf plasma 2

1000



01

Vivalytic
& Cartridges

Vivalytic

Molecular Diagnostics at the Point of Care

Vivalytic brings innovation to the Molecular Diagnostic testing market. It is the result of a successful collaboration between German technology expert, Bosch Healthcare Solutions and Randox Laboratories, a global IVD company and one of Bosch's first bio-content partners.

Bosch Healthcare Solutions has developed the Vivalytic system, which includes the test cartridge and analyser. Randox as the first partner on the Vivalytic platform, supplies Bosch with biological components needed inside the test cartridges to detect different pathogens in the samples. Furthermore, Randox distribute the Vivalytics analyser and test cartridges.

Vivalytic enables sample to result, cartridge-based Molecular Diagnostic testing. The Vivalytic platform is capable of both High-Plex and Low-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required.

No further peripherals such as a laptop, keyboard, barcode scanner or filling station are required, making Vivalytic a unique space-saving, hygienic solution for Molecular Diagnostic testing.



4-Step
Workflow



Unique
Test Menu



Fully
Automated



Fast
Test Results



High-Plex & Low-Plex
Capabilities



Wireless
Connectivity



Hi. Please **scan sample code** to begin.



vivalytic

Vivalytic Cartridges

Vivalytic cartridges are compact, technologically advanced Molecular Diagnostic tests utilising micro-fluidics to enable simple and accurate diagnostic testing. Vivalytic cartridges are powered by a variety of technologies, dependent upon the test application. High-Plex and Low-Plex tests can be analysed on the Vivalytic system. High-Plex tests utilise Randox patented Biochip Array Technology, enabling end-point qualitative PCR and providing multiple test results simultaneously from one patient sample. Low-Plex tests are based on a variety of detection methods including real-time qualitative PCR and melting curve analysis.



185mm (L) 75mm (W) 17mm (D)

*Actual Size



All Reagents On-Board



Room Temperature Storage



Multiplex Technology



Multiple Sample Types



Minimal Contamination Risk



High-Plex Vivalytic Cartridges

Powered by Randox Biochip Technology

Randox patented Biochip Technology allows simultaneous detection of multiple targets from a single patient sample. The biochip detection system is based on a chemiluminescent signal as a result of a chemical reaction.

Each biochip is prefabricated with spatially discrete testing regions (DTR's). Each DTR represents an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest. The High-Plex capabilities of Biochip Technology eliminates the need to run multiple time consuming and sample intensive assays.

Light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified with the Vivalytic device. The Vivalytic automatically generates a result report for all targets.




Vivalytic Workflow

4 Easy Steps for Optimised Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow. To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic. The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.



AWARD-WINNING DESIGN DELIVERS AN UNCOMPLICATED USER EXPERIENCE









02

Vivalytic
Test Menu

Respiratory



Viral Respiratory Tract Infections (VRI)

The Viral Respiratory Tract Infections (VRI) test cartridge detects 10 viral respiratory infections including SARS-CoV-2 in 2 hours 30 minutes. The panel provides a comprehensive respiratory virus screen detecting co-infections, enabling informed treatment decisions to be made.

Sample Type: Nasopharyngeal or Oropharyngeal Swab (eNAT)

Sample Volume: 300 µL

Detection Method: Radox Biochip Technology (end-point PCR)

Time to Result: 2 hours 30 minutes

VIRUSES	
SARS-CoV-2	Influenza A
Adenovirus A/B/C/D/E	Coronavirus OC43/HKU1
Sarbecovirus (SARS, SARS Like, SARS-CoV-2)	Influenza B
Enterovirus A/B/C/D / Rhinovirus A/B/C	Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Coronavirus 229E/NL63	Respiratory Syncytial Virus A/B (RSV)



SARS-CoV-2 Rapid Test

SARS-CoV-2 is a rapid real time PCR test cartridge, providing a clear and concise result in a timely manner. This enables the patient to take the recommended safety precautions.

Sample Type: Nasopharyngeal or Oropharyngeal Swab (eNAT)

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Time to Result: 39 minutes

VIRUS
SARS-CoV-2 (E gene sequence)



SARS-CoV-2 Rapid Pooling Test

The test provides a reliable SARS-CoV-2 result in 44 minutes and is currently one of the fastest PCR tests in the world. Pooling Cartridge can test up to 15 patient samples at one time.

Rapid SARS-CoV-2 pooling

Sample Type: Nasopharyngeal or Oropharyngeal Swab

Sample Volume: (150 µL per-patient sample. If less than 5 patient samples, supplement the remaining volume with eNAT solution).

Detection Method: Real-Time PCR

Time to Result: 44 minutes

15-fold lollipop pooling

Sample Type: Saliva using lollipop swab collection

Sample Volume: 750 µL (3 transport tubes of 250µl, each containing 5 lollipop swabs combined)

Detection Method: Real-Time PCR

Time to Result: 44 minutes

VIRUS
SARS-CoV-2 (E gene sequence)



SARS-CoV-2 Dual Target

SARS-CoV-2 dual target real time PCR cartridge provides clear and concise results in a timely manner, direct at the point of care. This enables individuals to take the recommended safety precautions without delay. The SARS-CoV-2 dual target rapid test allows for detection of both the E-gene and N-gene sequence.

Sample Type: Nasopharyngeal or Oropharyngeal Swab (eNAT)

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Time to Result: 53 minutes

VIRUS

SARS-CoV-2 (E gene and N gene sequence)



SARS-CoV-2, Flu A/B, and RSV

Patients infected with SARS-CoV-2, Influenza A (Flu A), Influenza B (Flu B) and/or Respiratory Syncytial Virus (RSV) have overlapping symptoms, but the approaches to patient management of infections caused by the viruses are different. SARS-CoV-2, Flu A/B, and RSV is a qualitative test for the rapid triage to support targeted treatment. The combination of these tests additionally reduces costs whilst addressing the challenge of respiratory infections at the point of care, facilitating infection control and risk assessment.

Sample Type: Nasopharyngeal or Oropharyngeal Swab (eNAT)

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Time to Result: 53 minutes

VIRUSES

SARS-CoV-2

Influenza A and Influenza B

Human Respiratory Syncytial Virus



Respiratory Tract Infections (RTI) *In Development*

The Respiratory Tract Infection (RTI) test cartridge is the most comprehensive screening test for infections of both the upper and lower respiratory tracts. It simultaneously detects 14 viral and 8 bacterial infections.

VIRUSES

Influenza A

Coronavirus OC43/HKU1

Parainfluenza virus 3

Influenza B

Enterovirus A/B/C

Parainfluenza virus 4

Adenovirus A/B/C/D/E

Metapneumovirus

Respiratory syncytial virus A/B

Bocavirus 1/2/3

Parainfluenza virus 1

Rhinovirus A/B/C

Coronavirus 229E/NL63

Parainfluenza virus 2

BACTERIA

Bordetella parapertussis

Haemophilus influenzae

Mycoplasma pneumoniae

Bordetella pertussis

Legionella pneumophila

Streptococcus pneumoniae

Chlamydomphila pneumoniae

Moraxella catarrhalis



Chronic Lung Disease (CLD) In Development

The Chronic Lung Disease (CLD) cartridge is a world leading multiplex test, detecting 131 species associated with long term lung disease e.g. Cystic Fibrosis and Chronic Obstructive Pulmonary Disease (COPD). The 131 species are simultaneously detected across this 31-plex array and includes bacterial, viral, fungal targets. Furthermore, the MecA antibiotic resistance marker is included to assist antibiotic stewardship.

VIRUSES			
Adenovirus	Respiratory syncytial virus A		
Influenza virus A	Respiratory syncytial virus B		
Influenza virus B	Rhinovirus A/B/C		

BACTERIA		
<i>Achromobacter xylosoxidans</i>	<i>Moraxella catarrhalis</i>	<i>Pseudomonas aeruginosa</i>
<i>Bordetella pertussis</i>	<i>Mycoplasma pneumoniae</i>	<i>Staphylococcus aureus</i>
<i>Burkholderia cepacia complex (21 spp)</i>	<i>Non-tuberculous Mycobacterium (17 spp)</i>	<i>Stenotrophomonas maltophilia</i>
<i>Burkholderia cenocepacia</i>	<i>Mycobacterium abscessus subgroup (4 spp)</i>	<i>Streptococcus pneumoniae (21 spp)</i>
<i>Burkholderia multivorans</i>	<i>Mycobacterium avium complex (4 spp)</i>	<i>Streptococcus species (19 spp)</i>
<i>Chlamydomphila pneumoniae</i>	<i>Pandora species (5 spp)</i>	<i>Veillonella species (3 spp)</i>
<i>Haemophilus influenzae</i>	<i>Prevotella species (16 spp)</i>	

FUNGI			
<i>Aspergillus fumigatus</i>	<i>Candida albicans</i>	<i>Exophiala dermatitidis</i>	<i>Scedosporium species (7 spp)</i>

ANTIBIOTIC RESISTANCE MARKERS
mecA (incl MRSA)



Vivalytic *Bordetella* CE

Bordetella pertussis is a gram-negative bacterium that causes acute respiratory infection called pertussis or whooping cough. Another cause of whooping cough or mild like symptoms can be caused by *Bordetella bronchiseptica*, *Bordetella holmesii* and *Bordetella parapertussis*.

Transmission of *Bordetella* infection is via droplet infection. Various methods are available for laboratory diagnosis- real-time PCR, culture, and serology.

Real-time PCR allows a rapid, sensitive, and specific detections up to 4 weeks after symptoms occur.

Sample Type: Nasopharyngeal swab sample

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Result Time: 47 minutes

DETECTABLE PATHOGENS		
<i>B. pertussis</i>	<i>B. parapertussis</i>	<i>B. holmesii</i>

Hospital Acquired Infections



MRSA/SA CE

MRSA/SA is a qualitative test detecting and differentiating between methicillin-resistant *Staphylococcus aureus* (MRSA), methicillin-sensitive *Staphylococcus aureus* (MSSA) and methicillin-resistant coagulase-negative *Staphylococci* (MRCoNS). By using one single cartridge, the Vivalytic MRSA/SA test aids in the diagnosis of MRSA infection in a speedy manner so that appropriate antibiotic treatment can be applied, and complications prevented.

Sample Type: Nasal or Oropharyngeal swab in liquid amies

Sample Volume: 600 µL

Detection Method: Real-Time PCR

Time to Result: 53 minutes

DETECTABLE PATHOGENS

Methicillin-resistant Staphylococcus aureus (MRSA)

Methicillin-sensitive Staphylococcus aureus (MSSA)

SPECIFIC GENE TARGETS

SCCmec/orfX junction, mecA/ mecC, SA422



Vivalytic *Candida auris*

Candida auris is an emerging and often multidrug-resistant fungal species that poses a significant threat to public health. This yeast-like fungus can cause severe infections, primarily affecting individuals with compromised immune systems, those in healthcare facilities, or those with underlying medical conditions. *Candida auris* is particularly concerning due to its ability to persist on surfaces, leading to healthcare-associated outbreaks. Diagnosis can be challenging as it is often misidentified with other *Candida* species. Effective management involves prompt identification, strict infection control measures followed by treatment.

The Vivalytic *Candida auris* test is an automated, qualitative in vitro diagnostic employing real-time PCR to detect *Candida auris* DNA from swabs taken from the human axilla, groin, nasal, and rectal areas. This test serves to screen individuals at risk for colonisation, playing a crucial role in the prevention and control of *Candida auris* outbreaks and infections within healthcare settings.

Sample Type: Nasal or Rectal Swab

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Result Time: Less than 1 hour

DETECTABLE PATHOGENS

Candida auris



Vivalytic Strep A *In Development*

Group A Streptococcus (GAS) is the primary culprit behind bacterial pharyngitis in school-aged children. Typically resulting in a mild illness characterised by symptoms such as a sore throat, headache, and fever, GAS infections may also manifest as scarlet fever, presenting with a fine, red rash. Although often manageable, severe cases warrant antibiotic treatment for effective resolution.

An automated, qualitative in vitro diagnostic test employing real-time polymerase chain reaction (PCR) is utilised to detect nucleic acids from *Streptococcus pyogenes* in human oropharyngeal swabs. This advanced test serves as a valuable aid in diagnosing streptococcal pharyngitis in symptomatic individuals.

Sample Type: Oropharyngeal swabs

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Result Time: Less than 30 minutes

DETECTABLE PATHOGENS

Streptococcus pyogenes



Vivalytic Bacterial Meningitis

Bacterial meningitis, an infectious disease-causing inflammation of the meninges, has significant global morbidity and mortality. Despite early diagnosis and adequate treatment, 8-15% of patients die within 24-48 hours of symptom onset.

Prompt and proper diagnosis and treatment are crucial to prevent death and lifelong disability among survivors. The introduction and widespread use of vaccines have led to a substantial decrease in meningitis cases, reducing global deaths by 21% from 1990 to 2016.

Young children are at the highest risk, with new-borns vulnerable to Group B streptococcus and young children at higher risk from meningococcus, pneumococcus, and *Haemophilus influenzae*. Meningococcal disease is a concern for young adults and adolescents, while pneumococcal disease poses a particular risk for the elderly.

Bacterial meningitis requires immediate antibiotic treatment, and point-of-care PCR tests using cerebrospinal fluid (CSF) offer promise in accelerating diagnosis by detecting multiple species simultaneously.

Sample Type: CSF

Sample Volume: 200 µL Clinical Sample

Detection Method: Real-time PCR

Result Time: 30 minutes

DETECTABLE PATHOGENS

Escherichia coli K1

Haemophilus influenzae

Listeria monocytogenes

Neisseria meningitidis

Streptococcus agalactiae

Streptococcus pneumoniae K1



Vivalytic Viral Meningitis **In Development*



Vivalytic *C. difficile* CE

Gastroenteritis is an inflammation of the stomach, small and large intestines. The majority of acute gastrointestinal illnesses (AGI) are caused by viruses such as Norovirus or Rotavirus but also bacterial pathogens such as *Clostridioides difficile* (*C. difficile*).

C. difficile is an anaerobic bacterium, widely distributed in soil and the intestinal tracts of animals. The clinical spectrum of *C. difficile* infection (CDI) ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis.

Transmission mostly takes place in healthcare institutions such as hospitals, patient to patient, contaminated hands of healthcare workers or by environmental contamination.

Sample Type: Swab samples from liquid or soft human stool specimens

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Result Time: Less than 50 minutes

DETECTABLE PATHOGENS

C. difficile (toxin genes *tcdA/tcdB*)



Vivalytic Norovirus CE

Gastroenteritis is an inflammation of the stomach, small and large intestines. The majority of acute gastrointestinal illnesses (AGI) are caused by viruses such as Norovirus or Rotavirus but also bacterial pathogens such as *Clostridioides difficile* (*C. difficile*).

Noroviruses are known as causing winter-vomiting disease or stomach-flu referring to their rapid spread in human populations especially during the winter period.

Norovirus causes most of all gastrointestinal infections and are highly contagious. Rotaviruses are the very cause of severe diarrhoeal illness in infants and young children.

Transmission mostly takes place in healthcare institutions such as hospitals, patient to patient, contaminated hands of healthcare workers or by environmental contamination.

Sample Type: Swab samples from liquid or soft human stool specimens

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Result Time: Less than 1 hour

DETECTABLE PATHOGENS

Norovirus (genogroup I/II)



Vivalytic Rota-, Norovirus & *C. diff*

Gastroenteritis is an inflammation of the stomach, small and large intestines. Most acute gastrointestinal illnesses (AGI) are caused by viruses such as Norovirus or Rotavirus but also bacterial pathogens such as *Clostridioides difficile* (*C. difficile*).

C. difficile is an anaerobic bacterium, widely distributed in soil and the intestinal tracts of animals. The clinical spectrum of *C. difficile* infection (CDI) ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis.

Norovirus causes most of all gastrointestinal infections and are highly contagious. Rotaviruses are the very cause of severe diarrhoeal illness in infants and young children.

Transmission mostly takes place in healthcare institutions such as hospitals, patient to patient, contaminated hands of healthcare workers or by environmental contamination.

Sample Type: Swab samples from liquid or soft human stool specimens

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Result Time: Less than 1 hour

DETECTABLE PATHOGENS

<i>Clostridioides difficile</i> genes (tcdA/tcdB)	Norovirus (genogroup I/ II)	Rotavirus type A
---	-----------------------------	------------------

Genitourinary



Sexually Transmitted Infections (STI)

The Sexually Transmitted Infections (STI) is the broadest cartridge-based STI panel on the market. The test simultaneously detects 10 bacterial, viral and protozoan infections for a comprehensive sexual health profile.

Sample Type: Swab or Urine (eNAT, Roche COBAS medium, or PBS)

Sample Volume: 300 µL

Detection Method: Randox Biochip Technology (end-point PCR)

Time to Result: 2 hours 20 minutes

INFECTIONS

Chlamydia trachomatis (CT)	Herpes simplex virus 1 (HSV-1)
Neisseria gonorrhoeae (NG)	Herpes simplex virus 2 (HSV-2)
Trichomonas vaginalis (TV)	Haemophilus ducreyi (HD)
Mycoplasma genitalium (MG)	Mycoplasma hominis (MH)
Treponema pallidum (Syphilis) (TP)	Ureaplasma urealyticum (UU)



MG, MH, UP/UU CE

Aiding in the diagnosis and containment of sexually transmitted infections (STIs) of symptomatic and asymptomatic individuals, the MG, MH, UP/UU test guides appropriate treatment decisions at the earliest opportunity for improved patient management, prevention of transmission and supporting emerging macrolide resistance. MG, MH, UP/UU belong to the group of human pathogenic bacterial species associated with STIs even though particularly *Ureaplasma* spp. are primarily considered as commensal organisms.

Sample Type: Swab (Urethral, Vaginal, Cervical, Rectal), Urine

Sample Volume: 300 µL Clinical Sample

Detection Method: Real-Time PCR

Time to Result: 53 minutes

BACTERIA		
<i>Mycoplasma genitalium</i>	<i>Mycoplasma hominis</i>	<i>Ureaplasma parvum/urealyticum</i>



Vivalytic UTI

Urinary tract infections are one of the most common infections to experience, affecting people worldwide. UTI's are classified as uncomplicated and complicated depending on underlying conditions.

One single native urine sample is used to screen for 16 uropathogens and 7 antibiotic resistance gene markers simultaneously

Sample Type: Native Urine

Sample Volume: 300 µL

Detection Method: Radox Biochip Technology (end-point PCR)

Result Time: 2.5 hours

DETECTABLE PATHOGENS		
GRAM-NEGATIVE BACTERIAL SPECIES	GRAM-POSITIVE BACTERIA SPECIES	ANTIMICROBIAL RESISTANCE GENES
<i>Acinetobacter baumannii</i>	<i>Enterococcus faecalis</i>	TRIMETHOPRIM RESISTANCE
<i>Enterobacter cloacae</i>	<i>Enterococcus faecium</i>	<i>dfrA1</i>
<i>Escherichia coli</i>	<i>Staphylococcus aureus</i>	<i>dfrA5</i>
<i>Klebsiella aerogenes</i>	<i>Staphylococcus epidermidis</i>	<i>dfrA17</i>
<i>Klebsiella oxytoca</i>	<i>Staphylococcus saprophyticus</i>	<i>dfrA12</i>
<i>Klebsiella pneumoniae</i>	<i>Streptococcus agalactiae</i>	METHICILLIN RESISTANCE
<i>Morganella morganii</i>		<i>mecA</i>
<i>Proteus</i> spp.		VANCOMYCIN RESISTANCE
<i>Providencia stuartii</i>		<i>vanA</i>
<i>Pseudomonas aeruginosa</i>		<i>vanB</i>



Vivalytic CT/NG *In Development

Isothermal amplification test for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*

Chlamydia trachomatis (CT) and *Neisseria gonorrhoeae* (NG) are bacterial sexually transmitted infections (STIs). Chlamydia, primarily transmitted through sexual contact, is often asymptomatic, necessitating testing for diagnosis. Symptoms may include painful urination, and if untreated, it can lead to complications like pelvic inflammatory disease. Gonorrhoeae, also transmitted sexually, presents symptoms such as painful urination and genital discharge. Early detection is crucial for both infections to prevent complications and further transmission.

Utilising isothermal nucleic amplification technology, our system qualitatively detects nucleic acids from *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG).

Sample Type: Swab or Urine

Sample Volume: 300 µL

Detection Method: Isothermal amplification

Result Time: 30 minutes

DETECTABLE PATHOGENS

Chlamydia trachomatis (incl. all serovars, nvCT)

Neisseria gonorrhoeae



Vivalytic CT/NG/MG/TV *In Development

Qualitative real-time PCR test for the detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium* and *Trichomonas vaginalis*

Chlamydia trachomatis is a bacterium responsible for one of the most common sexually transmitted infections (STIs), often asymptomatic and affecting the genital and ocular regions. *Neisseria gonorrhoeae* is another bacterial STI causing gonorrhoea, with symptoms including painful urination and genital discharge. *Mycoplasma genitalium* is a bacterium associated with urethritis in both men and women, often leading to discomfort and potential complications if untreated. *Trichomonas vaginalis* is a protozoan parasite causing trichomoniasis, a common STI with symptoms such as itching and discharge. Understanding these pathogens is crucial for early detection, prompt treatment, and preventing the spread of STIs.

This test aids in the diagnosis of these sexually transmitted infections (STIs) in symptomatic and asymptomatic patients.

Sample Type: Swab or Urine

Sample Volume: 300 µL

Detection Method: Real-Time PCR

Result Time: Less than 1 hour

DETECTABLE PATHOGENS

Chlamydia trachomatis

Neisseria gonorrhoeae

Mycoplasma genitalium

Trichomonas vaginalis

VIVALYTIC FASCINATES
WITH A MARKEDLY
MINIMALIST DESIGN
WHOSE STRENGTH
LIES IN ITS HIGH USER-
FRIENDLINESS AND
FUNCTIONALITY



reddot design award



BOSCH

x

00h09m24s

MP2

Amplification

Amplification

1 5 10 15 20 25 30 35 40 45 Cycles

1000000000

A


SARS-CoV-2

hoff

03

Vivalytic
Specifications

Vivalytic Specifications



TECHNICAL DATA

Display	7 inch 16:10, 1024 x 600 pixel touchscreen
Operating Air Pressure Range	850-1,100 hPa, corresponds to pressure range 0-1, 400m above sea level
Operating Temperature	15-30 °C
Storage Temperature	-20-60 °C
Data Transfer	Ethernet 10/100, MB, WLAN 2.4 GHz, (802.11b/g/n); internal: Bluetooth v4.1, 2.4 GHz (low energy), USB 2.0
Electromagnetic Compatibility	IEC/EN 61326-2-6, RED 2014/53/EC, FCC47 CFR 15
Dimensions	Length 400 mm, Width 204 mm, Height 388 mm
Distance/Space to the wall	~20 cm
Weight	15 kg
Storage Humidity	20-95 % (not condensing)
Operating Humidity	30-80 % (not condensing)
Electrical Data	100-240 V~, 50/60 Hz, 160 VA
Instrumental Safety	IEC/EN 61010-1, IEC/EN 61010-2-010 IEC/EN 61010-2-101, Regulation 2017/746
Memory Capacity	16 GB
Mean Loudness	≤ 55 dB(A) in operating mode. Short term loudness can exceed mean loudness
Socket	Use multiple sockets for EU countries and UK



Vivasuite

Vivasuite is a user-friendly digital ecosystem which allows users to reduce service costs and ensure the availability of their system. All Vivalytic analysers can be connected to Vivasuite, which is powered by the Bosch IoT Cloud and applies the highest standards regarding IT security and data privacy.

Functionality of the Vivasuite includes registration, device management and automatic software updates, giving the device administrators an informed perspective on the usage of the devices.

Benefits

- » Automatic software updates, including product releases
- » Real-time monitoring of internal machine performance
- » Monitoring of usage in remote settings



*Vivalytic analyser ready for third party plugins via HL7-Interface



vivalytic



04

Vivalytic
Ordering Information

Ordering Information

PRODUCT	QUANTITY	CATALOGUE NUMBER
Analyser		
Vivalytic One	x1	F09G300115
Test Cartridges		
Vivalytic STI	1 Kit (15 Cartridges)	F09G300078
Vivalytic MG, MH, UP/UU	1 Kit (15 Cartridges)	F09G300705
Vivalytic SARS-CoV-2, Flu A/B & RSV	1 Kit (15 Cartridges)	F09G300747
Vivalytic SARS-CoV-2	1 Kit (15 Cartridges)	F09G300411
Vivalytic SARS-CoV-2 Pooling	1 Kit (15 Cartridges)	F09G300587
Vivalytic SARS-CoV-2 DT	1 Kit (15 Cartridges)	F09G300711
Vivalytic MRSA/SA	1 Kit (15 Cartridges)	F09G300622
Vivalytic UTI	1 Kit (15 Cartridges)	F09G300385
Vivalytic Bordetella	1 Kit (15 Cartridges)	F09G300976
Vivalytic Candida auris	1 Kit (15 Cartridges)	F09G301061
Vivalytic Bacterial Meningitis	1 Kit (15 Cartridges)	F09G301009
Vivalytic C. difficile	1 Kit (15 Cartridges)	F09G300885
Vivalytic Norovirus	1 Kit (15 Cartridges)	F09G300879
Vivalytic Rota-, Norovirus & C. diff	1 Kit (15 Cartridges)	F09G300891
Vivalytic VRI Test	1 Kit (15 Cartridges)	F09G300636

MAKING A POINT TO CARE

55 Diamond Road,
Crumlin,
Co. Antrim,
United Kingdom,
BT29 4QY

Email. marketing@randox.com

Tel. +44 (0) 28 9442 2413

RANDOX

www.randox.com